• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

爱泼斯坦-巴尔病毒DNA在NK/T细胞淋巴瘤中的预后意义：一项荟萃分析

Prognostic significance of Epstein-Barr virus DNA in NK/T-cell lymphoma: a meta-analysis.

作者信息

Fei Qian, Tian Xiao-Kang, Wu Jing, Zhu Hong-Ming, Wang Yan, Peng Fan-Yu, Zhang Wen-Jun, Yin Li, He Xia

机构信息

Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, People's Republic of China.

出版信息

Onco Targets Ther. 2018 Feb 26;11:997-1004. doi: 10.2147/OTT.S153942. eCollection 2018.

DOI:10.2147/OTT.S153942
PMID:29520150
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5833780/
Abstract

Extranodal NK/T-cell lymphoma is closely associated with Epstein-Barr virus (EBV) infection. However, the prognostic value of EBV-DNA in extranodal NK/T-cell lymphoma remains unclear. Thus, we conducted a meta-analysis to estimate its prognostic significance. PubMed, EMBASE, and Web of Science were used to search for studies conducted until June 12, 2017. The pooled hazard ratio (HR) and its 95% confidence interval (CI) were calculated to evaluate the prognostic value of pretreatment EBV-DNA on the overall survival of extranodal NK/T-cell lymphoma. Seven eligible studies on 356 patients with extranodal NK/T-cell lymphoma were pooled for this meta-analysis. Results suggested that the pretreatment EBV-DNA positivity was significantly correlated with the overall survival of extranodal NK/T-cell lymphoma (pooled HR =3.78, 95% CI: 1.52-9.40, =0.004; heterogeneity test: =52%, =0.05). Subgroup analyses stratified by sample type, survival analysis mode, and HR origin showed that patients with positive pretreatment EBV-DNA had poorer prognosis than those with negative pretreatment EBV-DNA. Moreover, the cut-off value (HR =1.66; 95% CI: 0.73-3.73; =0.22) might account for the heterogeneity. No significant publication bias was observed. Pretreatment EBV-DNA positivity can predict poor prognosis for patients with extranodal NK/T-cell lymphoma. Future large-scale studies based on prognostic significance of EBV-DNA for patients with extranodal NK/T-cell lymphoma are necessary.

摘要

结外NK/T细胞淋巴瘤与EB病毒（EBV）感染密切相关。然而，EBV-DNA在结外NK/T细胞淋巴瘤中的预后价值仍不明确。因此，我们进行了一项荟萃分析以评估其预后意义。使用PubMed、EMBASE和科学网检索截至2017年6月12日进行的研究。计算合并风险比（HR）及其95%置信区间（CI），以评估治疗前EBV-DNA对结外NK/T细胞淋巴瘤总生存的预后价值。本荟萃分析纳入了7项关于356例结外NK/T细胞淋巴瘤患者的符合条件的研究。结果表明，治疗前EBV-DNA阳性与结外NK/T细胞淋巴瘤的总生存显著相关（合并HR =3.78，95% CI：1.52 - 9.40，P =0.004；异质性检验：I² =52%，P =0.05）。按样本类型、生存分析模式和HR来源分层的亚组分析显示，治疗前EBV-DNA阳性的患者预后比治疗前EBV-DNA阴性的患者差。此外，临界值（HR =1.66；95% CI：0.73 - 3.73；P =0.22）可能解释了异质性。未观察到显著的发表偏倚。治疗前EBV-DNA阳性可预测结外NK/T细胞淋巴瘤患者的预后不良。未来有必要开展基于EBV-DNA对结外NK/T细胞淋巴瘤患者预后意义的大规模研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667d/5833780/e8f3a7b12deb/ott-11-997Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667d/5833780/f1752df9895d/ott-11-997Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667d/5833780/ad95bd939023/ott-11-997Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667d/5833780/566a6378f3ab/ott-11-997Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667d/5833780/e8f3a7b12deb/ott-11-997Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667d/5833780/f1752df9895d/ott-11-997Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667d/5833780/ad95bd939023/ott-11-997Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667d/5833780/566a6378f3ab/ott-11-997Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667d/5833780/e8f3a7b12deb/ott-11-997Fig4.jpg

相似文献

1
Prognostic significance of Epstein-Barr virus DNA in NK/T-cell lymphoma: a meta-analysis.爱泼斯坦-巴尔病毒DNA在NK/T细胞淋巴瘤中的预后意义：一项荟萃分析
Onco Targets Ther. 2018 Feb 26;11:997-1004. doi: 10.2147/OTT.S153942. eCollection 2018.
2
Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.在使用天冬酰胺酶治疗的时代，治疗后血浆EBV-DNA阳性预示着结外NK/T细胞淋巴瘤患者早期复发及预后不良。
Oncotarget. 2015 Oct 6;6(30):30317-26. doi: 10.18632/oncotarget.4505.
3
Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type.前瞻性检测结外 NK/T 细胞淋巴瘤，鼻型患者血浆和外周血单个核细胞中的 EBV-DNA。
Blood. 2011 Dec 1;118(23):6018-22. doi: 10.1182/blood-2011-05-354142. Epub 2011 Oct 7.
4
Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.鼻型结外自然杀伤/T细胞淋巴瘤初次治疗结束后基于PET-CT的Deauville评分及EB病毒DNA状态进行风险分层：一项多中心回顾性分析
Lancet Haematol. 2015 Feb;2(2):e66-74. doi: 10.1016/S2352-3026(15)00002-2. Epub 2015 Jan 28.
5
Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.结外自然杀伤/T 细胞淋巴瘤患者缓解后循环 EBV DNA 监测的意义。
Ann Hematol. 2018 Aug;97(8):1427-1436. doi: 10.1007/s00277-018-3313-x. Epub 2018 Apr 8.
6
[Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].晚期结外NK/T细胞淋巴瘤的临床特征及预后分析
Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):462-468. doi: 10.3760/cma.j.issn.0253-2727.2020.06.005.
7
Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma.血浆中爱泼斯坦-巴尔病毒DNA在结外NK/T细胞淋巴瘤预后评估方面优于全血中的该病毒DNA 。
Front Oncol. 2020 Nov 30;10:594692. doi: 10.3389/fonc.2020.594692. eCollection 2020.
8
Prognostic implications of circulating Epstein-Barr virus DNA for extranodal natural killer/T-cell lymphoma, nasal type: a meta-analysis.循环 Epstein-Barr 病毒 DNA 对鼻型结外自然杀伤/T 细胞淋巴瘤的预后影响：一项荟萃分析
Cancer Manag Res. 2018 Jul 20;10:2183-2192. doi: 10.2147/CMAR.S162168. eCollection 2018.
9
Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.血清EBV EA-IgA和VCA-IgA抗体可用于结外NK/T细胞淋巴瘤的风险分层和预后预测：单机构24年经验
Ann Hematol. 2017 Aug;96(8):1331-1342. doi: 10.1007/s00277-017-3013-y. Epub 2017 May 27.
10
Evaluation of the role of Epstein-Barr virus in cases of nodal or extranodal T- and NK-cell lymphoma using eber in situ hybridization.使用爱泼斯坦-巴尔病毒编码的小RNA原位杂交评估爱泼斯坦-巴尔病毒在淋巴结或结外T细胞和NK细胞淋巴瘤病例中的作用。
Pol J Pathol. 2015 Jun;66(2):161-9. doi: 10.5114/pjp.2015.53013.

引用本文的文献

1
Risk stratification based on changes in the standard maximal uptake value on PET/CT and the plasma Epstein‒Barr virus (EBV) DNA status after two cycles of chemotherapy for extranodal NK-/T-cell lymphoma.基于正电子发射断层扫描/计算机断层扫描（PET/CT）标准最大摄取值的变化以及结外NK/T细胞淋巴瘤化疗两个周期后血浆EB病毒（EBV）DNA状态进行风险分层。
Ann Hematol. 2025 Jan;104(1):479-487. doi: 10.1007/s00277-024-06149-1. Epub 2024 Dec 27.
2
Comment on: Risk factors and prognosis of early death in secondary hemophagocytic lymphohistiocytosis.关于《继发性噬血细胞性淋巴组织细胞增生症早期死亡的危险因素及预后》的评论
Ann Hematol. 2024 Feb;103(2):693-694. doi: 10.1007/s00277-023-05504-y. Epub 2023 Oct 14.
3

本文引用的文献

1
The diagnosis and management of NK/T-cell lymphomas.NK/T细胞淋巴瘤的诊断与管理
J Hematol Oncol. 2017 Apr 14;10(1):85. doi: 10.1186/s13045-017-0452-9.
2
The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma.非霍奇金淋巴瘤患者外周血单个核细胞中EB病毒DNA的临床意义
Leuk Lymphoma. 2017 Oct;58(10):2349-2355. doi: 10.1080/10428194.2017.1300894. Epub 2017 Mar 17.
3
Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Extranodal natural killer/T-cell lymphoma nasal type.
鼻型结外自然杀伤细胞/T细胞淋巴瘤
Proc (Bayl Univ Med Cent). 2022 May 16;35(5):672-674. doi: 10.1080/08998280.2022.2071074. eCollection 2022.
4
Rhino-Orbital-Cerebral Mycosis and Extranodal Natural Killer or/and T-Cell Lymphoma, Nasal Type.鼻眶脑型真菌病与鼻型结外自然杀伤细胞或/和T细胞淋巴瘤
Front Med (Lausanne). 2022 Jun 17;9:851208. doi: 10.3389/fmed.2022.851208. eCollection 2022.
5
Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis.含依托泊苷方案在淋巴瘤相关噬血细胞性淋巴组织细胞增多症初始治疗中的必要性。
Cancer Biol Ther. 2021 Dec 2;22(10-12):598-606. doi: 10.1080/15384047.2021.1996139. Epub 2021 Nov 1.
6
How to Identify Patients at High Risk of Developing Nasal-Type, Extranodal Nature Killer/T-Cell Lymphoma-Associated Hemophagocytic Syndrome.如何识别发生鼻型、结外自然杀伤/T细胞淋巴瘤相关噬血细胞综合征高危患者。
Front Oncol. 2021 Aug 18;11:704962. doi: 10.3389/fonc.2021.704962. eCollection 2021.
7
Extranodal NK/T cell lymphoma, nasal type: a rare diagnosis with common nasal presentation.结外 NK/T 细胞淋巴瘤，鼻型：一种罕见的诊断，具有常见的鼻部表现。
BMJ Case Rep. 2021 Jun 22;14(6):e236436. doi: 10.1136/bcr-2020-236436.
8
Association between lncRNA H19 rs217727 polymorphism and the risk of cancer: an updated meta-analysis.长非编码 RNA H19 rs217727 多态性与癌症风险的关联：一项更新的荟萃分析。
BMC Med Genet. 2019 Nov 21;20(1):186. doi: 10.1186/s12881-019-0904-x.
9
Detection of EBV DNA in Non-Hodgkin Lymphoma Patients in Bulgaria.保加利亚非霍奇金淋巴瘤患者中EBV DNA的检测
Indian J Hematol Blood Transfus. 2019 Jul;35(3):465-470. doi: 10.1007/s12288-019-01088-8. Epub 2019 Jan 31.
10
Causes of mortality in cases with extra nodal natural killer/T-cell lymphoma, nasal type: A cohort study.结外鼻型自然杀伤/T 细胞淋巴瘤患者死亡原因：一项队列研究。
PLoS One. 2019 Apr 17;14(4):e0214860. doi: 10.1371/journal.pone.0214860. eCollection 2019.
结外NK/T细胞淋巴瘤，鼻型（ENKTL-NT）：北美和欧洲病例的流行病学、临床表现及自然史最新进展
Curr Hematol Malig Rep. 2016 Dec;11(6):514-527. doi: 10.1007/s11899-016-0355-9.
4
Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma.巨噬细胞炎性蛋白1α（MIP-1α）可能与结外NK/T细胞淋巴瘤患者的不良预后相关。
Hematol Oncol. 2017 Sep;35(3):310-316. doi: 10.1002/hon.2283. Epub 2016 Feb 29.
5
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.非蒽环类药物治疗后自然杀伤细胞淋巴瘤的预后指数：一项多中心回顾性分析。
Lancet Oncol. 2016 Mar;17(3):389-400. doi: 10.1016/S1470-2045(15)00533-1. Epub 2016 Feb 10.
6
The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases.EBV疾病患者与非EBV疾病患者血浆及外周血单个核细胞中EBV DNA的临床意义。
Blood. 2016 Apr 21;127(16):2007-17. doi: 10.1182/blood-2015-09-672030. Epub 2016 Jan 7.
7
Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.在使用天冬酰胺酶治疗的时代，治疗后血浆EBV-DNA阳性预示着结外NK/T细胞淋巴瘤患者早期复发及预后不良。
Oncotarget. 2015 Oct 6;6(30):30317-26. doi: 10.18632/oncotarget.4505.
8
Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.同步放化疗后序贯含L-天冬酰胺酶的化疗方案VIDL用于局限性鼻型结外NK/T细胞淋巴瘤：CISL08-01 II期研究
Ann Hematol. 2014 Nov;93(11):1895-901. doi: 10.1007/s00277-014-2137-6. Epub 2014 Jun 20.
9
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.限制平均生存时间：替代风险比的方法，用于设计和分析具有时间事件结局的随机试验。
BMC Med Res Methodol. 2013 Dec 7;13:152. doi: 10.1186/1471-2288-13-152.
10
Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance.SMILE 方案治疗的 NK/T 细胞淋巴瘤患者循环 EBV DNA 的定量检测：诊断和预后意义。
Leukemia. 2014 Apr;28(4):865-70. doi: 10.1038/leu.2013.212. Epub 2013 Jul 11.